Research Article

Pure ICL Implantation: A Novel Ophthalmic Viscosurgical Device-Free Method

Qin Qin,1,2,3 Lianyun Bao,1 Zifang He,1 Feifei Chen,1 Dandan Zhu,1 Si Zhang,1 Wenwen Zhang,1 Yajun Liu,1 Ruifying Gao,1 and Zhenggao Xie1

1Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu, China
2Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing 210008, Jiangsu, China
3Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210008, Jiangsu, China

Correspondence should be addressed to Qin Qin; qinqin.1219@hotmail.com and Zhenggao Xie; zhenggaoxie@163.com

Received 2 August 2021; Accepted 23 September 2021; Published 6 October 2021

Academic Editor: Suphi Taneri

Copyright © 2021 Qin Qin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To assess the clinical efficiency of a novel ophthalmic viscosurgical device-free (OVD-free) method for intraocular collamer lens (EVO-ICL) implantation in myopic eyes. Methods. In this study, 40 patients underwent ICL implantation for both eyes: one eye underwent traditional ICL implantation, and the other eye underwent OVD-free (pure) ICL implantation. Preoperative and postoperative UDVA, BCVA, equivalent spherical degree (SE), IOP, visual quality index, subjective visual quality scale, corneal endothelial cell density (ECD), operation time, and complications were compared between and within the traditional and pure ICL implantation groups. Results. Increased IOP > 22 mmHg 2h after surgery was noted in 8 eyes (20%) in the traditional group, but not in the pure group (0%, \( P < 0.001 \)). Increased IOP relative to baseline was significantly higher at 2h after surgery for the traditional group compared with the pure group (\( P < 0.001 \)). UDVA, BCVA, and SE were significantly improved in the pure group compared with those in the traditional group 1 day after implantation, but not in the pure group (0%, \( P < 0.001 \)). Increased IOP relative to baseline was significantly higher at 2h after surgery for the traditional group compared with the pure group (\( P < 0.001 \)). UDVA, BCVA, and SE were significantly improved in the traditional group 1 day after implantation, but not in the pure group (0%, \( P < 0.001 \)). No significant difference in ECD changes within or between groups was observed (\( P > 0.05 \)). Operation time for the pure group \( (2.897 \pm 0.346 \text{ min}) \) was significantly shorter than that for the traditional group \( (4.444 \pm 0.656 \text{ min}) \). No complications were reported for either group during the observation period, except early IOP elevation in the traditional group. Conclusions. The pure ICL implantation method was associated with faster visual acuity recovery, shorter operation time, and more stable intraocular pressure. Pure ICL represents a safe and convenient method for ICL implantation compared with the traditional method, completely eliminating OVD-related complications without causing additional complications.

1. Introduction

Myopia describes the condition in which the refractive system of the human eye focuses parallel light in front of the retina in a relaxed state [1]. In China, approximately 700 million people suffer from myopia, and 10% of those suffer from high myopia. Various surgical procedures can be used to correct myopia, including posterior chamber phakic intraocular lens (PIOL) implantation, small incision lenticule extraction (SMILE), and laser-assisted in situ keratomileusis (LASIK); however, the surgical options for high myopia patients with limited corneal thickness remain limited to lens replacement and PIOL implantation.

Visian ICL™ (STAAR Surgical, Nidau, Switzerland) is a type of posterior chamber PIOL [2, 3], and previous studies have shown that EVO-ICL (implantable collamer lens with a centre hole) implantation is satisfactorily safe [4]. EVO-ICL implantation can reduce the induction of high-order aberrations and improve contrast sensitivity [5]. Because the intraocular position of EVO-ICL is close to the eyeball node, magnification approaches 1, and the imaging size of external objects on the retina is similar to that for emmetropia, resulting
in EVO-ICL implantation patients presenting better visual quality than patients who undergo corneal refractive surgery. Features such as good postoperative visual acuity, visual quality, and reversibility have made EVO-ICL the first-line choice for an increasing number of patients with high myopia [6–12].

Traditional ICL implantation requires ophthalmic viscosurgical device (OVD) injection into the ICL implant container and the anterior chamber (AC) to maintain the operating space and protect the corneal endothelium and lens. Failure to completely clear OVD postoperatively can result in an acute increase in intraocular pressure (IOP) at the early postoperative stage [13–16]. Intraoperative OVD use may also increase the costs and time required for surgery [17]. Prolonged surgery and OVD irrigation using a syringe-coupled injection needle may increase the likelihood of contact between the ICL and the transparent lens, leading to early lens opacity after operation [18, 19]. The viscosity and electrostatic charge of OVD materials may result in the suspension of inflammatory cells in the AC, increasing the probability of postoperative inflammatory reactions. To address the adverse effects associated with OVD use, we developed a technology that uses a continuous infusion of balanced salt solution (BSS) through a side port, completely eliminating the need for OVDs during ICL implantation. We named this method “pure ICL implantation.” A preprint has previously been published [20]. In the present study, the double-pass technique (OQAS™ II, Optical Analysis System, Visiometrics, Spain) was used to assess optical quality indicators and intraocular objective scattering index (OSI) in patients who underwent either pure or traditional ICL implantation. The National Eye Institute Refractive Error Quality of Life Instrument-42 (NEI-RQL-42) scores were collected before and 3 months after surgery. The time of each surgery was recorded. Before the operation, 0.5% levofloxacin eye drops (Santen, Japan) were administered for 3 days to prevent infection. 0.1% fluorometholone eye drops (Santen, Japan) and 0.5% levofloxacin eye drops were administered 4 times a day for 2 weeks after the operation. Pranoprofen eye drops were also administered 3 times a day for 1 month after operation. In this study, the same doctor was in charge of all surgeries.

2. Patients and Methods

2.1. Patients. From 2018 to 2020, a total of 80 eyes in 40 patients (18 men and 22 women) underwent EVO-ICL implantation at Nanjing Drum Tower Hospital, affiliated with Nanjing University Medical School. One eye of every patient underwent the pure method, and the other underwent the traditional method. Patients with a history of eye surgery, severe dry eye, progressive corneal degeneration, cataracts, retinal detachment, or uveitis were excluded. The Institutional Review Board at Nanjing Drum Tower Hospital approved this study, which was performed in accordance with the tenets of the Declaration of Helsinki. All patients signed an informed consent concerning the risk of surgery.

2.2. Observation and Detection Indicators. Routine preoperative examinations were performed for all eyes, including UDVA, BCVA, scotopic pupil size, anterior segment examination under a slit lamp microscope, and retina examination, using three-mirror contact lenses. IOP was measured with a noncontact tonometer (Topcon Company, Japan). Optometry was performed using a CV-3000 comprehensive optometry testing machine (Topcon Company, Japan), including cycloplegic refraction and subjective optometry. The AC depth and corneal curvature were measured using an OCULYZER II (WaveLight, Alcon). A panoramic ultrasound biomicroscope (UBM) was used to study the anterior segment structures of the eye and measure the sulcus-to-sulcus (STS) distance, which was used to determine the ICL size. We calculated the ideal ICL size as STS +0.7 mm. Modulation transfer frequency (MTF), Strehl ratio (SR), three Optical Quality Analysis System (OQAS) contrast values (OV100%, OV20%, and OV9%), and objective scattering index (OSI) were detected by OQAS II. The ECD was measured using an SP-3000P corneal endothelial cell counter (Topcon Company, Japan). National Eye Institute Refractive Error Quality of Life Instrument-42 (NEI-RQL-42) scores were collected before and 3 months after surgery. The time of each surgery was recorded. Before the operation, 0.5% levofloxacin eye drops (Santen, Japan) were administered for 3 days to prevent infection. 0.1% fluorometholone eye drops (Santen, Japan) and 0.5% levofloxacin eye drops were administered 4 times a day for 2 weeks after the operation. Pranoprofen eye drops were also administered 3 times a day for 1 month after operation. In this study, the same doctor was in charge of all surgeries.

2.3. Anterior Chamber Maintainer (ACM). The anterior chamber maintainer (ACM), with a 0.4 mm diameter and 1.5 mm length, was designed by our group and produced by an ophthalmic instrument company. The head was bevelled at a small angle (60°) to facilitate access to the AC through the side incision (Figure 1).

2.4. Surgical Procedures

2.4.1. Traditional ICL Implantation. Before surgery, the eyes were instilled with compound tropicamide eye drops (Santen, Japan) 4 times to expand the pupil diameter to greater than 7 mm. Oxybuprocaine hydrochloride (Santen, Japan) eye drops were applied 4 times as topical anaesthesia. A small OVD amount (1.7% sodium hyaluronate, Shandong Bausch and Lomb Freda Company) and balanced salt solution (BSS, Alcon, USA) were injected into the ICL implant container. The injector was properly installed and placed in BSS for later use. An assisted right-side incision was made, through which an appropriate OVD amount was injected into the AC. A 3.0 mm clear corneal main incision was made, typically placed on the steep axis of the corneal curvature, to release corneal astigmatism. The ICL was inserted from the main incision of the AC, and a sufficient OVD amount was injected into the front surface of the ICL to maintain
the operating space. After gently tucking the footplate beneath the iris and adjusting the ICL to a central position, the OVD was manually irrigated from the AC using BSS by an injection needle attached to a syringe. Finally, the incisions were made watertight.

2.4.2. Pure ICL Implantation. Before surgery, dilated pupil and surface anaesthesia were the same as the traditional methods. The ICL implant container was filled only with BSS, and the ICL injector was installed properly and placed in BSS for later use. Symmetrical assisted incisions were made on the right and left sides, approximately 0.4 mm wide, and the ACM was placed in the left incision. A 3.0 mm transparent corneal main incision was performed, typically located on the steep axis of the corneal curvature, to release corneal astigmatism. The ICL was inserted from the main incision into the AC, gently tucking the footplates beneath the iris and adjusting the ICL to a central position. Finally, the incisions were made watertight.

2.5. Management of Early Acute IOP Elevation. Early IOP elevation was defined as an increase in IOP >22 mmHg within 2 h after surgery. If early IOP elevation was detected, a slit lamp examination was performed to eliminate pupil block or malignant glaucoma caused by excessive vault. If IOP was only slightly elevated (IOP <25 mmHg), close observation was performed. For moderately elevated IOP (IOP = 25–30 mmHg), topical antiglaucoma medications were administered. For significantly elevated IOP (IOP >30 mmHg), AC drainage was performed once through the side incision, with or without the administration of topical antiglaucoma medication, to reduce IOP to 10–13 mmHg. After treatment, IOP was measured every 2 h until a normal value was achieved.

2.6. Statistical Analysis. Collected data were entered into Microsoft Excel (Microsoft Co. WA, USA) and analysed using Statistical Package for the Social Sciences (SPSS, version 20; IBM Inc., Armonk, USA). Descriptive and inferential statistical analyses were performed. At the descriptive level, continuous parameters were evaluated for parameter normality and are reported as the mean ± standard deviation (SD). At the inferential level, an independent t-test, a paired-sample t-test, the Mann–Whitney U test, and the one-way analysis of variance (ANOVA) were performed. A P value of less than 0.05 was considered significant.

3. Results
3.1. General Data. No significant differences in age, gender, preoperative SE, UDVA, or BCVA were identified between the two treatment groups (Table 1).
3.2. Comparison of IOP between the Two Groups. The average IOP of the pure group is $13.730 \pm 2.172$, $15.550 \pm 2.438$, $14.150 \pm 2.070$, $13.880 \pm 2.267$, and $13.630 \pm 2.618$ before operation and 2h, 1 day, 1 week, and 3 months after operation, respectively, compared with $13.550 \pm 2.342$, $20.575 \pm 2.890$, $14.275 \pm 1.948$, $13.780 \pm 2.304$, and $13.380 \pm 2.906$ in the traditional group. Preoperative IOP was within the normal range for both groups with no significant difference ($P = 0.730$). A significant difference in the time course of IOP changes was observed between the two groups. At 2h after operation, no patients in the pure group (0%) had IOP $>22$ mmHg compared with 8 patients in the traditional group (20%). One patient in the traditional group experienced mild eye pain and corneal oedema, with an IOP of 31 mmHg 2h after operation. After performing AC drainage and administering carteol chloride drops twice, the symptoms disappeared within 24h, and IOP decreased to 18 mmHg. Higher IOP values of the other 7 patients were 23, 24, 24, 23, 26, 25 mmHg. Two of them (25, 26 mmHg) were given carteol chloride 2 times. One day after operation, both groups presented IOP $<22$ mmHg.

At 2h after surgery, the IOP values in the pure group were significantly lower than those in the traditional group ($P < 0.001$). At 1 day, 1 week, and 3 months after the operation, no significant differences in IOP were observed between groups ($P = 0.782, 0.845, 0.687$; Figure 2).

A significant difference in IOP was observed before and 2h after operation in both groups ($P < 0.001$), but no significant differences were observed between other time points (Figures 3 and 4).

The differences between postoperative and preoperative baseline IOP values in the pure group were $1.83 \pm 0.96$, $0.43 \pm 1.55, 0.15 \pm 2.02, and -0.1 \pm 1.58$ at 2h, 1 day, 1 week, and 3 months after surgery, respectively, compared with $7.03 \pm 2.99, 0.73 \pm 1.41, 0.23 \pm 2.01$, and $-0.18 \pm 1.84$ in the traditional group. The differences between baseline and 2h postoperative IOP values were significantly lower in the pure group than in the traditional group ($P < 0.001$). At 1 day, 1 week, and 3 months after surgery, no significant differences were observed between groups ($P = 0.369, 0.868, 0.845$; Figure 5).

3.3. Comparison of Visual Acuity and Refractive Power between the Pure and Traditional ICL Implantation Groups. Table 2 shows the visual acuity and refractive power values of both groups. The intragroup comparisons showed increased UDVA and BCVA values for both groups 3 months after surgery compared with preoperative values. Postoperative SE values were significantly lower than preoperative values ($P < 0.001$).

At 1 day after surgery, the UDVA and BCVA values of the pure group were significantly better than those of the traditional group ($P < 0.001$). No significant differences between groups were observed before and 1 week and 3 months after surgery.

On postoperative day 1, the SE of the pure group was significantly lower than that of the traditional group ($P = 0.003$). No significant difference in SE was observed between groups at the other time points.

3.4. Comparison of Visual Quality between Pure and Traditional ICL Implantation Groups. Table 3 shows the OQAS II visual quality indicators for patients in the pure group before surgery and 1 day, 1 week, and 3 months after surgery. The MTF cut-off frequencies at 1 day and 1 week after surgery were significantly lower than those before surgery ($P < 0.001$ and $P = 0.014$). The SR value 1 day after surgery was significantly lower than that before surgery ($P = 0.025$). The OV100% values 1 day and 1 week after surgery ($P < 0.001$ and $P = 0.002$) and the values of OV20% and OV9% 1 day after surgery ($P < 0.001$ and $P < 0.001$) were significantly lower than the corresponding preoperative values. No significant differences were observed in other OQAS II visual quality indicators between preoperative and postoperative time points. The OSI values 1 day and 1 week after surgery were higher than those before surgery ($P < 0.001$), but no significant difference in OSI values was observed 3 months after surgery and before surgery.

Table 4 shows the OQAS II visual quality indicators for patients in the traditional group before surgery and 1 day, 1 week, and 3 months after surgery. The MTF cut-off frequency, SR, OV100%, OV20%, and OV9% values 1 day ($P < 0.001, P < 0.001, P < 0.001, P < 0.001, and P < 0.001$) and 1 week ($P = 0.005, P < 0.001, P = 0.003, P < 0.001$, and $P < 0.001$) after surgery were lower than the corresponding preoperative values. No significant differences in any OQAS II visual quality indicators were observed before and 3 months after surgery. The OSI values 1 day and 1 week after surgery were significantly higher than that before surgery ($P < 0.001, P = 0.003$, respectively), but no significant difference in OSI values was observed before and 3 months after surgery.

Table 5 compares the visual quality indicators of patients undergoing the two surgical methods. We compared visual quality between the two groups before and 1 day, 1 week, and 3 months after surgery. At 1 day after surgery, the MTF cut-off frequency, SR, and OV20% values of the pure group were significantly higher than those of the traditional group ($P = 0.013, P = 0.009$, and $P = 0.004$). One week after surgery, the SR, OV20%, and OV9% values of the pure group were significantly higher than those in the traditional group ($P = 0.003, P = 0.047$, and $P = 0.002$). The remaining values did not differ significantly at any time point.

3.5. NEI-RQL-42 Scores. Patients filled out the NEI-RQL-42 before and 3 months after surgery and scored as described by the instructions: the average value of each item = the sum of all points per item/the number of questions per item. Table 6 shows the within-group comparisons in NEI-RQL-42 scores before and 3 months after surgery. At 3 months after surgery, except for a decrease in glare and no significant increase in near vision, all indicators were significantly higher than those before surgery ($P < 0.05$) for both groups.
Table 7 shows the between-group comparison in NEI-RQL-42 scores before and 3 months after surgery. No significant differences in scores were observed between the two groups.

3.6. Comparison of Corneal ECD before and after Operation within and between the Pure and Traditional ICL Implantation Groups. Table 8 shows no significant differences in corneal ECD between the pure and traditional groups either before or three months after surgery (P > 0.05). No significant differences were observed between these two time points within each group (P > 0.05).

3.7. Operation Time and Complications. The mean operation time for the pure group was 2.897 ± 0.346 min, which was significantly shorter than the operation time of 4.444 ± 0.656 min for the traditional group (P < 0.001, Figure 6).

The vault measurements for all postoperative eyes in both groups were between 1/2 corneal thickness (CT) and 3/2 CT at each time point after surgery. Except for early postoperative IOP elevation in some patients, no serious complications, such as posterior corneal elastic layer detachment, cataract development, pupil block, iris injury, or pigment dispersion, occurred during the intraoperative or 3-month follow-up periods.

4. Discussion

Through the continuous development and improvement in ICL implantation technology, the EVO-ICL implant with a central hole has become the most mainstream surgical method for intraocular refractive surgery, favored by patients with high myopia and other refractive errors who are not satisfied with or do not qualify for corneal laser surgery [21]. The safety and efficacy of ICL implantation have been widely recognized [3, 12]. During traditional ICL implantation procedures, OVDs should be injected into the ICL implant container and the eyes to reduce the potential for damage to the corneal endothelium and transparent lens and to maintain the AC space for surgery. However, residual OVDs have been associated with increased or abnormal IOP, lens opacity, and slow vision recovery [13–16, 18, 19]. Blumenthal [22], Tak [23], Fatih [24], Bardoloi [25], and other researchers have used various ACM devices to avoid the use of OVDs during phacoemulsification cataract extraction or intraocular lens implantation. Pan [26] introduced ICL implantation with continuous infusion and a single-handed ACM. Its safety and effectiveness have been confirmed. Pan is the only study to date that used ACM for ICL implantation. However, the use of Pan’s ACM requires one hand, which limits the coordination of activities that require two hands, such as eye movement. Therefore, we developed a hands-free, operationally convenient ACM. Under continuous infusion conditions, the ICL implantation could be performed without the use of OVDs, referred to as pure ICL implantation. This method reduces the operation time, promotes the early recovery of vision, and is beneficial for controlling increases in IOP and reducing...
complications associated with residual OVDs. Pure ICL implantation was found to be effective and worthy of clinical application.

During traditional ICL implantation, the use of OVDs is essential. OVDs function to fill, protect, and lubricate the AC [27, 28]. In this study, the pure ICL implantation method used a continuous BSS infusion through a side port, to eliminate the use of OVDs. Therefore, the ICL spreads faster and does not contact the lens or corneal endothelium, and the flushing process applied to remove OVDs is no longer necessary, resulting in a shortened operation time to approximately 3 min, which was significantly shorter than the time necessary for the traditional method, reducing the risk of corneal endothelial damage associated with prolonged operation times, reducing material costs, and improving the experience of both patients and doctors.

A large number of studies [5, 14–16, 21, 29] have shown that early postoperative IOP elevation is a common complication due to residual OVDs following ICL implantation using traditional methods. The intraoperative use of various types of OVDs may also affect IOP recovery. Gonzalez-Lopez [14] implanted V4c ICL in 100 eyes, among which 5 eyes experienced increased IOP 3–6 hours after surgery. They hypothesised that residual OVDs (2% hydroxypropyl methyl cellulose) blocked the trabecular meshwork or the central hole of the ICL, resulting in increased IOP. Almalki [15] found that, out of 534 patients after ICL implantation, 58 patients experienced IOP elevation, including 23 patients with IOP elevation on the first day after surgery (the OVD was 1% sodium hyaluronate). Senthil [16] found that, in patients with high IOP after ICL implantation, 27% of cases were caused by OVD residues (2% hydroxypropyl methyl cellulose), including 2 cases with pupil block due to OVD residue. Our study showed that 2 h after surgery more patients (20%) in the traditional ICL implantation group had IOP >22 mmHg compared with the pure ICL implantation group (0%). The IOP of the traditional group was similar to previous studies.

The differences between the 2 h IOP values and the preoperative baseline IOP values were significantly lower in the pure ICL implantation group than those in the traditional ICL implantation group. The IOP values for both groups returned to normal levels at 1 day, 1 week, and 3 months after surgery, with no significant differences between groups or compared with their preoperative baseline IOP values. The results showed that avoiding OVD use was beneficial for controlling early postoperative IOP elevation and promoting the recovery of IOP after surgery.

The evaluation of visual quality after refractive surgery typically includes both objective and subjective detection methods, such as the objective visual quality indicators measured by OQASII, the intraocular OSI, and the subjective visual quality scale reported by patients [30–32]. In this study, the OQAS™ II double-pass retinal imaging technology was used to analyse the visual quality of the target by collecting data from the 780 nm laser diode light intensity distribution on retinal imaging. The point light source resolution of an optical system is described by the point spread function (PSF). During the analysis of optical imaging quality, the visual quality indicators, including the MTF cut-off frequency, SR, and OVs at various contrast sensitivities (OV9%, OV20%, and OV100%), and the OSI are derived from the PSF. The results of this study showed that the MTF, SR, OV100%, and OV20% values of patients in the pure group 1 day after surgery and the SR, OV20%, and OV9% values in the pure group 1 week after surgery were higher than those in the traditional group. These results suggested that the visual quality of patients in the pure group was better than that of patients in the traditional group during the early postoperative stage. Correspondingly, the UDVA and CDVA of the pure group 1 day after surgery were also higher than those of the traditional group. These differences were thought to be related to the higher IOP, the
Table 2: Time courses of the visual and refractive outcomes between the pure ICL implantation and the traditional ICL implantation groups.

|                      | Preoperative period | 1 day | Postoperative period | 1 week | 3 months | P value |
|----------------------|---------------------|-------|----------------------|--------|----------|---------|
| LogMAR UDVA          |                     |       |                      |        |          |         |
| Pure method          | 1.283 ± 0.226       | 0.008 ± 0.66 | −0.038 ± 0.067 | −0.038 ± 0.067 | P9 < 0.001* |
| Traditional method   | 1.23 ± 0.219        | 0.07 ± 0.085 | −0.025 ± 0.084 | −0.042 ± 0.071 | P9 < 0.001* |
| P value              | P1 = 0.295          | P1 ≤ 0.001* | P1 = 0.463         | P1 = 0.747 |          |         |
| LogMAR BCVA          |                     |       |                      |        |          |         |
| Pure method          | 0.165 ± 0.103       | −0.01 ± 0.071 | −0.055 ± 0.064 | −0.058 ± 0.071 | P9 < 0.001* |
| Traditional method   | 0.182 ± 0.098       | 0.048 ± 0.096 | −0.03 ± 0.082 | −0.058 ± 0.075 | P9 < 0.001* |
| P value              | P1 = 0.439          | P1 = 0.003* | P1 = 0.133         | P1 = 0.345 |          |         |

Spherical equivalent (D)

|                      | Preoperative period | 1 day | Postoperative period | 1 week | 3 months | P value |
|----------------------|---------------------|-------|----------------------|--------|----------|---------|
| Pure method          | −11.306 ± 1.314     | −0.13 ± 0.253 | −0.156 ± 0.202 | −0.175 ± 0.206 | P9 < 0.001* |
| Traditional method   | −11.638 ± 1.431     | 0.044 ± 0.259 | −0.113 ± 0.16 | −0.144 ± 0.169 | P9 < 0.001* |
| P value              | P1 = 0.284          | P1 = 0.003* | P1 = 0.285         | P1 = 0.460 |          |         |

Note. P9: P value of the difference between the preoperative and three-month values; P1: P value of the difference between the pure ICL implantation and the traditional ICL implantation groups; *P < 0.05: significant difference. LogMAR: logarithm of the minimal angle of resolution; UDVA: uncorrected distance visual acuity; BCVA: best-corrected distance visual acuity; D: diopter.

Table 3: Time courses of the optical quality parameters after pure ICL implantation.

|                      | Preoperative period | 1 day | Postoperative period | 1 week | 3 months | P value |
|----------------------|---------------------|-------|----------------------|--------|----------|---------|
| MTF cut-off frequency (cpd) | 48.48 ± 5.24       | 42.91 ± 6.15 | 45.32 ± 3.60 | 48.88 ± 3.92 |          |         |
| P value              | P1 < 0.001*        | P2 < 0.014* | P2 = 0.951         | P2 = 0.614 |          |         |
| SR                   | 0.25 ± 0.06        | 0.23 ± 0.04 | 0.25 ± 0.06        | 0.26 ± 0.06 |          |         |
| P value              | P1 = 0.252*        | P2 = 0.951 | P2 = 1.52 ± 0.15   | 1.58 ± 0.16 |          |         |
| OV100%               | 1.63 ± 0.16        | 1.43 ± 0.20 | 1.52 ± 0.15        | 1.58 ± 0.16 |          |         |
| P value              | P1 < 0.001*        | P2 = 0.002* | P2 = 1.000         | P2 = 1.000 |          |         |
| OV20%                | 1.26 ± 0.20        | 1.10 ± 0.14 | 1.15 ± 0.23        | 1.27 ± 0.20 |          |         |
| P value              | P1 < 0.001*        | P2 = 0.147 | P2 = 1.47          | P2 = 1.000 |          |         |
| OV9%                 | 0.71 ± 0.18        | 0.57 ± 0.12 | 0.70 ± 0.14        | 0.72 ± 0.12 |          |         |
| P value              | P1 < 0.001*        | P2 = 1.000 | P2 = 1.000         | P2 = 1.000 |          |         |
| OSI                  | 0.41 ± 0.11        | 0.60 ± 0.16 | 0.57 ± 0.16        | 0.43 ± 0.11 |          |         |
| P value              | P1 < 0.001*        | P2 = 0.001* | P2 = 0.945         |          |          |         |

Note. P1: P value of the difference in the visual quality parameters before surgery and one day after surgery; P2: P value of the difference in the visual quality parameters before surgery and one week after surgery; P3: P value of the difference in the visual quality parameters before surgery and three months after surgery. *P < 0.05: significant difference. MTF: modulation transfer function; OSI: objective scattering index; OV: OQAS value.

Table 4: Time courses of the optical quality parameters after traditional ICL implantation.

|                      | Preoperative period | 1 day | Postoperative period | 1 week | 3 months | P value |
|----------------------|---------------------|-------|----------------------|--------|----------|---------|
| MTF cut-off frequency (cpd) | 47.82 ± 4.18       | 39.79 ± 4.78 | 43.83 ± 4.47 | 47.97 ± 3.93 |          |         |
| P value              | P1 < 0.001*        | P2 < 0.001* | P2 = 0.880         | P2 = 0.880 |          |         |
| SR                   | 0.26 ± 0.05        | 0.21 ± 0.03 | 0.22 ± 0.03        | 0.27 ± 0.05 |          |         |
| P value              | P1 < 0.001*        | P2 < 0.001* | P2 = 0.998         | P2 = 0.998 |          |         |
| OV100%               | 1.62 ± 0.14        | 1.36 ± 0.26 | 1.44 ± 0.28        | 1.60 ± 0.15 |          |         |
| P value              | P1 < 0.001*        | P2 = 0.005* | P2 = 0.987         | P2 = 0.987 |          |         |
| OV20%                | 1.23 ± 0.26        | 1.01 ± 0.15 | 1.06 ± 0.15        | 1.18 ± 0.26 |          |         |
| P value              | P1 < 0.001*        | P2 = 0.003* | P2 = 0.960         | P2 = 0.960 |          |         |
| OV9%                 | 0.72 ± 0.14        | 0.56 ± 0.08 | 0.62 ± 0.08        | 0.70 ± 0.17 |          |         |
| P value              | P1 < 0.001*        | P2 < 0.001* | P2 = 0.989         | P2 = 0.989 |          |         |
| OSI                  | 0.41 ± 0.12        | 0.60 ± 0.19 | 0.55 ± 0.21        | 0.43 ± 0.11 |          |         |
| P value              | P1 < 0.001*        | P2 = 0.003* | P2 = 0.992         | P2 = 0.992 |          |         |

Note. P1: P value of the difference in the visual quality parameters before surgery and one day after surgery; P2: P value of the difference in the visual quality parameters before surgery and one week after surgery; P3: P value of the difference in the visual quality parameters before surgery and three months after surgery. *P < 0.05: significant difference. MTF: modulation transfer function; OSI: objective scattering index; OV: OQAS value.
Table 5: Time courses of the visual quality indicators in the pure ICL implantation and traditional ICL implantation groups.

|                          | Before operation | 1 day after operation | 1 week after operation | 3 months after operation |
|--------------------------|------------------|-----------------------|------------------------|--------------------------|
| MTF cut-off frequency    | Pure method      | Traditional method   | Pure method            | Traditional method       |
| Value                    | P = 0.53         | P = 0.013             | P = 0.010              | P = 0.301                |
| SR                       | 0.25 ± 0.06      | 0.26 ± 0.05           | 0.23 ± 0.04            | 0.21 ± 0.03              |
| Value                    | P = 0.614        | P = 0.009             | P = 0.003              | P = 0.707                |
| OV100%                   | 1.63 ± 0.16      | 1.62 ± 0.14           | 1.43 ± 0.20            | 1.36 ± 0.26              |
| Value                    | P = 0.653        | P = 0.161             | P = 0.149              | P = 0.655                |
| OV20%                    | 1.26 ± 0.20      | 1.23 ± 0.26           | 1.10 ± 0.14            | 1.01 ± 0.15              |
| Value                    | P = 0.619        | P = 0.004             | P = 0.007              | P = 0.116                |
| OV9%                     | 0.71 ± 0.18      | 0.72 ± 0.14           | 0.57 ± 0.12            | 0.56 ± 0.08              |
| Value                    | P = 0.689        | P = 0.577             | P = 0.002              | P = 0.630                |
| OSI                      | 0.41 ± 0.11      | 0.41 ± 0.12           | 0.60 ± 0.16            | 0.60 ± 0.19              |
| Value                    | P = 0.850        | P = 0.932             | P = 0.762              | P = 0.954                |

Note. P: P value of the difference between visual quality indicators in the pure ICL implantation and traditional ICL implantation groups; *P < 0.05: significant difference; MTF: modulation transfer function; OSI: objective scattering index; OV = OQAS value.

Table 6: NEI-RQL-42 scores before and 3 months after surgery in the pure ICL implantation and traditional ICL implantation groups.

|                          | Pure method      | Traditional method |
|--------------------------|------------------|--------------------|
| Value                    | P value          | P value            |
| Total score              | 60.568 ± 3.772   | 83.685 ± 2.675     |
| Clarity of vision        | 64.327 ± 2.894   | 87.045 ± 3.184     |
| Expectation              | 30.500 ± 3.558   | 81.436 ± 3.448     |
| Near vision              | 81.508 ± 3.361   | 83.720 ± 3.105     |
| Far vision               | 81.920 ± 3.687   | 77.835 ± 2.589     |
| Visual fatigue           | 74.548 ± 2.447   | 87.687 ± 2.288     |
| Activity limitations     | 40.516 ± 3.346   | 70.596 ± 3.300     |
| glare                    | 73.504 ± 3.083   | 70.643 ± 3.721     |
| Symptoms                 | 73.155 ± 3.114   | 81.244 ± 3.383     |
| Dependence on correction | 28.493 ± 1.818   | 98.288 ± 0.952     |
| Worry                    | 49.473 ± 2.213   | 75.534 ± 3.333     |
| Suboptimal correction    | 74.518 ± 3.777   | 89.625 ± 3.951     |
| Appearance               | 48.555 ± 3.042   | 90.819 ± 3.666     |
| Satisfaction with correction | 58.498 ± 3.490 | 90.211 ± 3.704     |

Note. P: P value of NEI-RQL-42 scores statistically compared before and 3 months after surgery in the pure ICL implantation and traditional ICL implantation groups; *P < 0.05: the difference is statistically significant.

Table 7: NEI-RQL-42 scores before and 3 months after surgery in the pure ICL implantation and traditional ICL implantation groups.

|                          | Pre               | 3 mo post            |
|--------------------------|-------------------|----------------------|
| Value                    | P value           | P value              |
| Total score              | 60.568 ± 3.772    | 83.685 ± 2.675       |
| Clarity of vision        | 64.327 ± 2.894    | 87.045 ± 3.184       |
| Expectation              | 30.500 ± 3.558    | 81.436 ± 3.448       |
| Near vision              | 81.508 ± 3.361    | 83.720 ± 3.105       |
| Far vision               | 81.920 ± 3.687    | 77.835 ± 2.589       |
| Visual fatigue           | 74.548 ± 2.447    | 87.687 ± 2.288       |
| Activity limitations     | 40.516 ± 3.346    | 70.596 ± 3.300       |
| glare                    | 73.504 ± 3.083    | 70.643 ± 3.721       |
| Symptoms                 | 73.155 ± 3.114    | 81.244 ± 3.383       |
| Dependence on correction | 28.493 ± 1.818    | 98.288 ± 0.952       |
| Worry                    | 49.473 ± 2.213    | 75.534 ± 3.333       |
| Suboptimal correction    | 74.518 ± 3.777    | 89.625 ± 3.951       |
| Appearance               | 48.555 ± 3.042    | 90.819 ± 3.666       |
| Satisfaction with correction | 58.498 ± 3.490 | 90.211 ± 3.704       |

Note. P value: NEI-RQL-42 scores before and 3 months after surgery statistically compared between the pure ICL implantation and the traditional ICL implantation groups.
The presence of residual OVDs, and the longer operation times in the traditional group, which caused AC inflammatory responses. No significant differences in objective visual quality indicators and subjective visual quality scale scores were observed between the two groups at 3 months after surgery, which indicated that both groups had good visual quality at 3 months after surgery.

The cornea is an important component of the refractive system of the eye. The maintenance of corneal thickness and transparency depends on the structural and functional integrity of corneal endothelial cells [33, 34]. The excessive loss of corneal endothelial cells can lead to the decompensation of corneal endothelial cell function, irreversible corneal oedema, and severe damage to visual function [35]. Corneal endothelial cells play decisive roles in the maintenance of normal physiological function in corneal tissues and are completely exposed to a nonphysiological environment during ICL implantation. Corneal endothelial cells can come into direct contact with perfusion fluid, viscoelastic agents, surgical instruments, and ICL, making them vulnerable to various factors. In previous EVO-ICL implantation studies using OVDs, Cao [36] reported a corneal endothelial cell loss rate of approximately 2% at 6 months after surgery. Lisa [37] reported a rate of 1.7% at 12 months after surgery. Pan [26] found that the rate was approximately 4.6% at 3 months after surgery. In this study, the loss rate of corneal endothelial cells in the pure group was approximately 2%, whereas that in the traditional group was approximately 2.3% at 3 months after surgery. No significant differences were observed before and after surgery for either group. The results showed that the pure group in this study was not associated with additional damage to corneal endothelial cells, with an outcome similar to the use of OVDs. The lack of additional corneal injury caused by continuous BSS perfusion in the pure group may be due to the shorter operation time in the pure group (2.897 ± 0.346 min), which was nearly half that of the traditional group. The AC remained stable during the operation, reducing the risk of mechanical injury due to the operation. In addition, the equilibrium liquefaction composition of BSS is similar to that of aqueous humour. BSS is nontoxic with mild properties and can maintain the pH and osmotic pressure of the AC. In addition, in this study, the BSS perfusion time was short, the flow rate was slow, and the perfusion pressure was appropriate. The continuous application of perfusion fluid could remove intraoperative exudates, tissue fragments, and blood clots, effectively reducing the risk of corneal endothelial cell injury and postoperative inflammatory reactions. In this study, no lesions of the transparent lens were observed in either group intraoperatively or 3 months after surgery, which indicated that pure ICL implantation could safely avoid the occurrence of OVD-related complications, such as corneal endothelial cell death and clear lens injury.

This study has some limitations. The observation time was short, and the sample size was relatively small. In the future, we will expand the sample size and extend the observation time.

5. Conclusions

In conclusion, the results of this study indicated that the pure ICL implantation method could avoid OVD-related IOP elevation, reducing the necessity and risk of IOP reduction management strategies, including the use of anti-glaucoma drugs and AE discharge. Pure ICL is a safe and reliable method with clinical application that can reduce the postoperative inflammatory reaction, shorten the operation time, and reduce operating costs.

**Abbreviations**

ICL: Intraocular collamer lens  
OV: OQAS II values  
OSI: Objective scatter index  
MTF: Modulation transfer function  
UDVA: Uncorrected distance visual acuity  
BCVA: Best-corrected distance visual acuity.

**Data Availability**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethical Approval

The Institutional Review Board at Nanjing Drum Tower Hospital approved this study, which followed the tenets of the Declaration of Helsinki.

Consent

All patients signed an informed consent concerning the risks of surgery.

Disclosure

A preprint has previously been published [20]. The funding agencies had no role in the design or conduct of this study—including collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript—or in the decision to submit the manuscript for publication.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

QQ contributed to design, manuscript drafting, data acquisition, analysis, and interpretation. LYB was responsible for design and operator. ZFH performed data acquisition and analysis. FFC carried out data acquisition, analysis, and manuscript drafting. DDZ, RYG, SZ, WWZ, and YJL conducted data acquisition. ZGX participated in design, manuscript drafting, data acquisition, and analysis. All the authors read and approved the final manuscript.

Acknowledgments

This work was supported by the Fundamental Research Funds of the Central Universities (0214-14380487).

References

[1] D. M. Hornbeak and T. L. Young, “Myopia genetics: a review of current research and emerging trends,” Current Opinion in Ophthalmology, vol. 20, no. 5, pp. 356–362, 2009.
[2] M. Packer, “The Implantable Collamer Lens with a central port: review of the literature,” Clinical Ophthalmology, vol. 12, pp. 2427–2438, 2018.
[3] R. Wei, M. Li, H. Zhang et al., “Comparison of objective and subjective visual quality early after implantable collamer lens V4c (ICL V4c) and small incision lenticule extraction (SMILE) for high myopia correction,” Acta Ophthalmologica, vol. 98, no. 8, pp. e943–e950, 2020.
[4] M. R. Bloomenstein, D. D. Dulaney, R. W. Barnet, and S. A. Perkins, “Posterior chamber phakic intraocular lens for moderate myopia and hyperopia,” Optometry, vol. 73, no. 7, pp. 435–446, 2002.
[5] K. Shimizu, K. Kamiya, A. Igarashi, and T. Shiratani, “Early clinical outcomes of implantation of posterior chamber phakic intraocular lens with a central hole (Hole ICL) for moderate to high myopia,” British Journal of Ophthalmology, vol. 96, no. 2, pp. 409–412, 2012.
[6] K. Shimizu, K. Kamiya, A. Igarashi, and T. Shiratani, “Intraindividual comparison of visual performance after posterior chamber phakic intraocular lens with and without a central hole implantation for moderate to high myopia,” American Journal of Ophthalmology, vol. 154, no. 3, pp. 486–494, 2012.
[7] D. Huang, S. C. Schallhorn, A. Sugar et al., “Phakic intraocular lens implantation for correction of Myopia: A report by the American Academy of Ophthalmology,” Ophthalmology, vol. 116, no. 11, pp. 2244–2258, 2009.
[8] A. Barsam and B. D. Allan, “Excimer laser refractive surgery versus phakic intraocular lenses for the correction of moderate to high myopia,” Cochrane Database of Systematic Reviews, vol. 6, Article ID CD007679, 2014.
[9] A. Barsam and B. D. S. Allan, “Meta-analysis of randomized controlled trials comparing excimer laser and phakic intraocular lenses for myopia between 6.0 and 20.0 diopters,” Cornea, vol. 31, no. 4, pp. 454–461, 2012.
[10] N. S. Tsiklis, G. D. Kymionis, C. L. Karp, T. Naoumidi, and A. I. Pallikaris, “Nine-year follow-up of a posterior chamber phakic IOL in one eye and LASIK in the fellow eye of the same patient,” Journal of Refractive Surgery, vol. 23, no. 9, pp. 935–937, 2007.
[11] Q. Qin, Z. Wu, L. Bao et al., “Evaluation of visual quality after EVO-ICL implantation for hypermyopia: an observational study,” Medicine, vol. 98, no. 44, Article ID e17677, 2019.
[12] Q. Qin, L. Bao, L. Yang, Z. He, and Z. Huang, “Comparison of visual quality after EVO-ICL implantation and SMILE to select the appropriate surgical method for high myopia,” BMC Ophthalmology, vol. 19, no. 1, 21 pages, 2019.
[13] P. Fernandes, J. M. González-Méjome, D. Madrid-Costa, T. Ferrer-Blasco, J. Jorge, and R. Montés-Micó, “Implantable collamer posterior chamber intraocular lenses: a review of potential complications,” Journal of Refractive Surgery, vol. 27, no. 10, pp. 765–776, 2011.
[14] F. Gonzalez-Lopez, R. Bilbao-Calabuig, B. Mompean et al., “Intraocular pressure during the early postoperative period after 100 consecutive implantations of posterior chamber phakic intraocular lenses with a central hole,” Journal of Cataract and Refractive Surgery, vol. 39, no. 12, pp. 1859–1863, 2013.
[15] S. Almalki, A. Abubaker, N. A. Alsabaani, and D. P. Edward, “Causes of elevated intraocular pressure following implantation of phakic intraocular lenses for myopia,” International Ophthalmology, vol. 36, no. 2, pp. 259–265, 2016.
[16] S. Senthil, N. S. Choudhari, P. K. Vaddavalli, S. Murthy, J. C. Reddy, and C. S. Garudadri, “Etiology and management of raised intraocular pressure following posterior chamber phakic intraocular lens implantation in myopic eyes,” PLoS One, vol. 11, no. 11, Article ID e0165469, 2016.
[17] H. Bissen-Miyajima, “Ophthalmic viscosurgical devices,” Current Opinion in Ophthalmology, vol. 19, no. 1, pp. 50–54, Article ID e17677, 2008.
[18] B. Lackner, S. Pieh, G. Schmidinger et al., “Long-term results of implantation of phakic posterior chamber intraocular lenses,” Journal of Cataract and Refractive Surgery, vol. 30, no. 11, pp. 2269–2276, 2004.
[19] C. é. A. Sánchez-Galeana, R. J. Smith, D. R. Sanders et al., “Lens opacities after posterior chamber phakic intraocular lens implantation,” Ophthalmology, vol. 110, no. 4, pp. 781–785, 2003.
[20] Q. Qin, L. Bao, Z. He et al., “Pure ICL implantation: a novel ophthalmic viscosurgical device-free technique,” Research square, preprint, 2021.
[21] K. Kamiya, K. Shimizu, A. Igarashi et al., ”Posterior chamber phakic intraocular lens implantation: comparative, multi-centre study in 351 eyes with low-to-moderate or high myopia,” British Journal of Ophthalmology, vol. 102, no. 2, pp. 177–181, 2018.

[22] M. Blumenthal, E. I. Assia, V. Chen, and I. Avni, ”Using an anterior chamber maintainer to control intraocular pressure during phacoemulsification,” Journal of Cataract & Refractive Surgery, vol. 20, no. 1, pp. 93–96, 1994.

[23] H. Tak, ”Hydroimplantation: foldable intraocular lens implantation without an ophthalmic viscosurgical device,” Journal of Cataract and Refractive Surgery, vol. 36, no. 3, pp. 377–379, 2010.

[24] F. Özcura and S. Çevik, ”Hydroimplantation versus viscoimplantation: comparison of intraocular lens implantation with and without ophthalmic viscoelastic device in phacoemulsification,” Romanian Journal of Ophthalmology, vol. 62, no. 4, pp. 282–287, 2018.

[25] N. Bardoloi, S. Sarkar, A. Pilania, and H. Das, ”Pure phaco: phacoemulsification without ophthalmic viscosurgical devices,” Journal of Cataract and Refractive Surgery, vol. 46, no. 2, pp. 174–178, 2020.

[26] A.-P. Pan, L.-J. Wen, X. Shao et al., ”A novel ophthalmic viscosurgical device-free phakic intraocular lens implantation makes myopic surgery safer,” Eye and Vision, vol. 7, no. 1, p. 18, 2020.

[27] M. O. Price and F. W. Price, ”Evaluation of the toric implantable collamer lens for simultaneous treatment of myopia and astigmatism,” Expert Review of Medical Devices, vol. 12, no. 1, pp. 25–39, 2015.

[28] A. Olivo-Payne, A. Gomez-Bastar, A. Lichtinger, A. Ramirez-Miranda, E. O. Graue-Hernandez, and A. Navas, ”More than a decade of experience with implantable collamer lens,” Journal of Refractive Surgery, vol. 31, no. 12, p. 854, 2015.

[29] J. S. Chang and A. Y. Meau, ”Visian Collamer phakic intraocular lens in high myopic Asian eyes,” Journal of Refractive Surgery, vol. 23, no. 1, pp. 17–25, 2007.

[30] L. Niu, H. Miao, M. Tian, D. Fu, X. Wang, and X. Zhou, ”One-year visual outcomes and optical quality of femtosecond laser small incision lenticule extraction and visian implantable collamer lens (ICL V4c) implantation for high myopia,” Acta Ophthalmologica, vol. 98, no. 6, pp. e662–e667, 2020.

[31] H. Miao, X. Chen, M. Tian, Y. Chen, X. Wang, and X. Zhou, ”Refractive outcomes and optical quality after implantation of posterior chamber phakic implantable collamer lens with a central hole (ICL V4c),” BMC Ophthalmology, vol. 18, no. 1, p. 141, 2018.

[32] C. Pérez-Vives, T. Ferrer-Blasco, D. Madrid-Costa, S. García-Lázaro, and R. Montés-Micó, ”Visual quality comparison of conventional and Hole-Visian implantable collamer lens at different degrees of decentering,” British Journal of Ophthalmology, vol. 98, no. 1, pp. 59–64, 2014.

[33] H. Suzuki, T. Igarashi, T. Shiwa, and H. Takahashi, ”Efficacy of ophthalmic viscosurgical devices in preventing temperature rise at the corneal endothelium during phacoemulsification,” Current Eye Research, vol. 41, no. 12, pp. 1548–1552, 2016.

[34] H. Goukon, K. Kamiya, K. Shimizu, and A. Igarashi, ”Comparison of corneal endothelial cell density and morphology after posterior chamber phakic intraocular lens implantation with and without a central hole,” British Journal of Ophthalmology, vol. 101, no. 11, pp. 1461–1465, 2017.

[35] D. M. Stăniliă, A. M. Florea, A. Stăniliă, and A. A Panga, ”Endothelial cells loss to the hyperopic patients during phacoemulsification,” Romanian journal of ophthalmology, vol. 61, no. 4, pp. 256–260, 2017.

[36] X. Cao, W. Wu, Y. Wang, C. Xie, J. Tong, and Y. Shen, ”Posterior chamber collagen copolymer phakic intraocular lens with a central hole for moderate-to-high myopia: first experience in China,” Medicine, vol. 95, no. 36, Article ID e4641, 2016.

[37] C. Lisa, M. Naveiras, B. Alfonso-Bartolozzi, L. Belda-Salmerón, R. Montés-Micó, and J. F. Alfonso, ”Posterior chamber collagen copolymer phakic intraocular lens with a central hole to correct myopia: one-year follow-up,” Journal of Cataract and Refractive Surgery, vol. 41, no. 6, pp. 1153–1159, 2015.